"Generic drugs are experiencing faster sales growth than many branded ones, and this trend is set to continue," says visiongain

San Francisco, CA and London, UK; 16 November 2005: Generic pharmaceutical products are becoming an ever important part of the major pharmaceutical markets. In fact in 2004 the total world market for generic prescription drugs was $39.6bn and it is set to rise to $83.9bn by 2010. These are the findings of visiongain's latest report "The World's Top Ten Generic Companies 2005". With over 39 major drugs due to lose their patent protection before 2010, generic companies are prepared to gain even further market share. Visiongain predicts that there will be sustained increases in growth through 2005-2007, but that there will be a peak in the period 2008-2010.

Visiongain also reveals that nine of the top ten fastest growing pharmaceutical companies are generic as a result of the increasing demand for cheaper drugs. This high growth market is especially important as branded drug growth rates are beginning to falter for the same forecast period.

Report author Dr Gordon Low said: "It is a constantly changing market with companies merging to improve overall competitive position."

The study examines crucial aspects of the top ten generic companies, including recent acquisitions and mergers as well as the latest financial results of each. The report also covers the latest generic company strategies, the success and failure of the Hatch-Waxman Act, European regulatory issues, and important litigation in the sector.

ENDS

http://www.bioportfolio.com/cgi-bin/acatalog/The_World_s_Top_Ten_Generic_Companies.html